论文部分内容阅读
突触结合蛋白I-C2A片段(SytI-C2A)具有与活化血小板膜表面的磷脂酰丝氨酸(PS)特异结合的能力。本研究通过动物实验初步探讨99Tcm标记突触结合蛋白I-C2A片段(99Tcm-SytI-C2A)作为显像剂用于进行急性静脉血栓显像的可行性。选择比格犬5只,通过导管将双股螺旋金属丝送入一侧后肢股静脉,制成急性股静脉血栓模型;然后静脉注射99Tcm-SytI-C2A185MBq,注射后1h、2h和3h分别进行显像,用勾画“感兴趣”区的方法计算血栓部位与对侧后肢的对称部位以及血栓/本底的放射性比值。取出血栓、后肢肌肉和血液等标本,体外测定%ID·g-1值。结果表明,注射后1h、2h和3h,血栓部位与对侧后肢对称部位的放射性比值分别为3.01±0.30、3.22±0.21和3.37±0.57;与同侧下肢放射性本底的比值分别为3.10±0.39、3.32±0.31和3.50±0.45。体外检测结果显示出股静脉血栓的单位质量放射性摄取量是血液的2.40±0.35倍,是后肢肌肉的68.90±45.30倍。99Tcm-SytI-C2A能用于无创性地早期检测静脉血栓,有望成为较理想的新型血栓显像剂。
The synaptotagmin I-C2A fragment (SytI-C2A) has the ability to specifically bind to phosphatidylserine (PS) on the surface of activated platelet membranes. This study was to investigate the feasibility of using 99Tcm-labeled synaptotagmin I-C2A fragment (99Tcm-SytI-C2A) as an imaging agent for acute venous thrombectomy in animal experiments. Five Beagle dogs were selected and double-stranded helical wires were delivered to the dorsal femoral vein through a catheter to make an acute femoral vein thrombosis model. Then intravenous 99Tcm-SytI-C2A185MBq was injected intravenously at 1h, 2h and 3h after injection For example, calculate the radiological ratio of the thrombus site to the contralateral hind limb symmetry site and the thrombus / background using the method outlined in the “area of interest”. Blood samples such as thrombus, hindlimb muscle and blood were taken, and the value of% ID · g-1 was determined in vitro. The results showed that the ratios of radioactivity of thrombus and symmetrical parts of contralateral hind limbs at 3.0h, 0.12 and 3.37 ± 0.57 respectively at 1h, 2h and 3h after injection were 3.10 ± 0.39 , 3.32 ± 0.31 and 3.50 ± 0.45, respectively. In vitro test results showed that the unit mass radioactivity of femoral vein thrombosis was 2.40 ± 0.35 times that of blood and 68.90 ± 45.30 times of hindlimb muscle. 99Tcm-SytI-C2A can be used for non-invasive early detection of venous thrombosis, is expected to become a more ideal new thrombotic imaging agent.